Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Briacell Therapeutics Corp (BCTX)

Briacell Therapeutics Corp (BCTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 21,458
  • Shares Outstanding, K 1,884
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,310 K
  • EBIT $ -27 M
  • EBITDA $ -27 M
  • 60-Month Beta 1.38
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.33

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.93 +81.10%
on 11/20/25
13.00 -3.46%
on 12/03/25
+1.24 (+10.96%)
since 11/07/25
3-Month
6.93 +81.10%
on 11/20/25
14.68 -14.51%
on 10/21/25
+4.57 (+57.17%)
since 09/08/25
52-Week
6.00 +109.17%
on 08/25/25
190.50 -93.41%
on 12/10/24
-131.03 (-91.26%)
since 12/06/24

Most Recent Stories

More News
BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

Three poster presentations at the San Antonio Breast Cancer Symposium (SABCS), now available and to be presented on December 10, 2025, highlight robust survival and clinical benefit data in Phase 2, plus...

BCT.TO : 17.39 (+10.06%)
BCTXW : 0.0447 (-3.04%)
BCTXZ : 0.4100 (unch)
BCTX : 12.55 (+10.18%)
BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

Three poster presentations at the San Antonio Breast Cancer Symposium (December 10, 2025) will highlight positive Phase 2 safety and efficacy signals and positive biomarker findings in both the Phase 2...

BCT.TO : 17.39 (+10.06%)
BCTXW : 0.0447 (-3.04%)
BCTXZ : 0.4100 (unch)
BCTX : 12.55 (+10.18%)
BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Collaboration uses Receptor AI's platform to design highly selective anti-cancer kinase inhibitor products for BriaPro, a BriaCell subsidiary Partnership expected to expand BriaPro's small-molecule...

BCT.TO : 17.39 (+10.06%)
BCTXW : 0.0447 (-3.04%)
BCTXZ : 0.4100 (unch)
BCTX : 12.55 (+10.18%)
BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Three BriaCell poster presentations include updated key biomarker data from BriaCell’s pivotal Phase 3 study and updated survival data from the Phase 2 study of Bria-IMT™ plus immune check point inhibitor...

BCT.TO : 17.39 (+10.06%)
BCTXW : 0.0447 (-3.04%)
BCTXZ : 0.4100 (unch)
BCTX : 12.55 (+10.18%)
BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+â„¢ at SITC 2025

Next generation Bria-OTS+ platform demonstrates rapid, potent and durable anti-cancer activity by activating both innate and adaptive immune responses Increased tumor cell cytotoxicity induced by...

BCT.TO : 17.39 (+10.06%)
BCTXW : 0.0447 (-3.04%)
BCTXZ : 0.4100 (unch)
BCTX : 12.55 (+10.18%)
BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+â„¢ in Breast and Prostate Cancer Models

SITC poster to be presented on Friday, November 7, 2025, emphasizes robust anti-cancer activity of next generation Bria-OTS+ platform Lead candidates Bria-BRES+â„¢ (breast cancer) and Bria-PROS+â„¢...

BCT.TO : 17.39 (+10.06%)
BCTXW : 0.0447 (-3.04%)
BCTXZ : 0.4100 (unch)
BCTX : 12.55 (+10.18%)
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Independent DSMB has identified no safety concerns, and recommends continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitor Fourth consecutive positive DSMB...

BCT.TO : 17.39 (+10.06%)
BCTXW : 0.0447 (-3.04%)
BCTXZ : 0.4100 (unch)
BCTX : 12.55 (+10.18%)
BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

79 clinical sites across 23 US states are currently enrolling patients in BriaCell’s pivotal Phase 3 study in metastatic breast cancer (MBC)  Dartmouth Cancer Center, Cedars-Sinai Medical Center,...

BCT.TO : 17.39 (+10.06%)
BCTXW : 0.0447 (-3.04%)
BCTXZ : 0.4100 (unch)
BCTX : 12.55 (+10.18%)
BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+â„¢ for Breast Cancer

Collaboration with MSK’s Therapeutics Accelerator Program includes manufacturing, IND and clinical development support of the Bria-OTS+™ platform, which includes Bria-BRES+™ for breast cancer...

BCT.TO : 17.39 (+10.06%)
BCTXW : 0.0447 (-3.04%)
BCTXZ : 0.4100 (unch)
BCTX : 12.55 (+10.18%)
BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

Biomarkers identified in BriaCell’s Phase 2 study are showing similar and encouraging trends in the ongoing pivotal Phase 3 study of Bria-IMT™ in metastatic breast cancer (MBC) No new safety or...

BCT.TO : 17.39 (+10.06%)
BCTXW : 0.0447 (-3.04%)
BCTXZ : 0.4100 (unch)
BCTX : 12.55 (+10.18%)

Business Summary

BriaCell Therapeutics Corp. is an immuno-oncology focused biotechnology company. It developed a patented whole-cell vaccine, cancer immunotherapy technology called the `BriaVax` vaccine for cancer. The company's technology consists of Bria-IMT(TM), Bria-OTS(TM) and BriaDx(TM) which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 14.18
2nd Resistance Point 13.44
1st Resistance Point 12.99
Last Price 12.55
1st Support Level 11.80
2nd Support Level 11.06
3rd Support Level 10.61

See More

52-Week High 190.50
Fibonacci 61.8% 120.02
Fibonacci 50% 98.25
Fibonacci 38.2% 76.48
Last Price 12.55
52-Week Low 6.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar